MERTK and neoplasm: In these studies, MRX-2843 not only directly targets leukemic cells but also reprograms the tumor microenvironment by suppressing immunosuppressive macrophage signaling, offering a dual mechanism of action through both tumor-intrinsic and immune-mediated pathways (127, 128, 130, 135).Together, these findings underscore the importance of MerTK and Axl in myeloid-mediated immune tolerance and provide a strong rationale for their continued development as therapeutic targets to reprogram the TME and improve cancer immunotherapy outcomes.